Targeting nicotinamide N-methyltransferase decreased aggressiveness of osteosarcoma cells.
anti-cancer therapy
cell migration
cell proliferation
molecular biomarker
nicotinamide N-methyltransferase
osteosarcoma
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
revised:
07
02
2024
received:
31
08
2023
accepted:
12
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Osteosarcoma (OS) is a primary bone malignancy that mostly affects young people, characterized by high metastatic potential, and a marked chemoresistance that is responsible for disease relapse in most patients. Therefore, it is necessary to identify novel molecules to setup targeted strategies to improve the clinical outcome. The enzyme nicotinamide N-methyltransferase (NNMT) catalyses the N-methylation of nicotinamide and other analogs, playing a crucial role in the biotransformation of drugs and xenobiotics. NNMT overexpression was reported in a wide variety of cancers, and several studies demonstrated that is able to promote cell proliferation, migration and resistance to chemotherapy. The aim of this study was to explore the potential involvement of NNMT in OS. Immunohistochemical analyses have been performed to evaluate NNMT expression in selected OS and healthy bone tissue samples. Subsequently, OS cell lines have been transfected with vectors targeting NNMT mRNA (shRNAs) and the impact of this downregulation on migration, cell proliferation, and response to chemotherapeutic treatment was also analysed by wound healing, MTT, SRB and Trypan blue assays, respectively. Results showed that OS samples display a significantly higher NNMT expression compared with healthy tissue. Preliminary results suggest that NNMT silencing in OS cell lines is associated to a decrease of cell proliferation and migration, as well as to enhanced sensitivity to chemotherapy. Data obtained showed that NNMT may represent an interesting marker for OS detection and a promising target for effective anti-cancer therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Osteosarcoma (OS) is a primary bone malignancy that mostly affects young people, characterized by high metastatic potential, and a marked chemoresistance that is responsible for disease relapse in most patients. Therefore, it is necessary to identify novel molecules to setup targeted strategies to improve the clinical outcome. The enzyme nicotinamide N-methyltransferase (NNMT) catalyses the N-methylation of nicotinamide and other analogs, playing a crucial role in the biotransformation of drugs and xenobiotics. NNMT overexpression was reported in a wide variety of cancers, and several studies demonstrated that is able to promote cell proliferation, migration and resistance to chemotherapy. The aim of this study was to explore the potential involvement of NNMT in OS.
METHODS
METHODS
Immunohistochemical analyses have been performed to evaluate NNMT expression in selected OS and healthy bone tissue samples. Subsequently, OS cell lines have been transfected with vectors targeting NNMT mRNA (shRNAs) and the impact of this downregulation on migration, cell proliferation, and response to chemotherapeutic treatment was also analysed by wound healing, MTT, SRB and Trypan blue assays, respectively.
RESULTS
RESULTS
Results showed that OS samples display a significantly higher NNMT expression compared with healthy tissue. Preliminary results suggest that NNMT silencing in OS cell lines is associated to a decrease of cell proliferation and migration, as well as to enhanced sensitivity to chemotherapy. Data obtained showed that NNMT may represent an interesting marker for OS detection and a promising target for effective anti-cancer therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14185Informations de copyright
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online. 2021;20(1):24.
Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39-50.
Anna MC, Kamil S, Wiktoria F, et al. Molecular biology of osteosarcoma. Cancers (Basel). 2020;12(8):2130.
Amirhossein M, Amanda G, Moayd A, Anna AK. Osteosarcoma: a comprehensive review. SICOT-J. 2018;4:12.
Weixuan W, Changmei Y, Tianxiang W, Haiteng D. Complex roles of nicotinamide N-methyltransferase in cancer progression. Cell Death Dis. 2022;13(3):267.
Pozzi V, Campagna R, Sartini D, Emanuelli M. Nicotinamide N-Methyltransferase as promising tool for Management of Gastrointestinal Neoplasms. Biomolecules. 2022;12(9):1173.
Sartini D, Molinelli E, Pozzi V, et al. Immunohistochemical expression of nicotinamide N-methyltransferase in lymph node metastases from cutaneous malignant melanoma. Hum Cell. 2023;36(1):480-482.
Campagna R, Pozzi V, Spinelli G, et al. The utility of nicotinamide N-Methyltransferase as a potential biomarker to predict the oncological outcomes for urological cancers: an update. Biomolecules. 2021;11(8):1214.
Li XY, Pi YN, Chen Y, Zhu Q, Xia BR. Nicotinamide N-Methyltransferase: a promising biomarker and target for human cancer therapy. Front Oncol. 2022;12:894744.
Togni L, Mascitti M, Sartini D, et al. Nicotinamide N-Methyltransferase in head and neck tumors: a comprehensive review. Biomolecules. 2021;11(11):1594.
Ganzetti G, Sartini D, Campanati A, et al. Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma. Melanoma Res. 2018;28(2):82-88.
Pompei V, Salvolini E, Rubini C, et al. Nicotinamide N-methyltransferase in nonmelanoma skin cancers. Eur J Clin Invest. 2019;49(12):e13175.
Papi A, Farabegoli F, Iori R, et al. Vitexin-2-O-xyloside, raphasatin and (−)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells. Food Chem. 2013;138:1521-1530.
Teeny SM, York SC, Mesko JW, Ruth ER. Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American association of hip and knee Surgeons' member survey. J. Arthroplasty. 2003;18(8):954-962.
Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075-1085.
Zuch D, Giang A, Shapovalov Y, et al. Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem. 2012;113(4):1282-1291.
Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015;16:2727-2736.
Campagna R, Cecati M, Pozzi V, et al. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Mol Biol (Noisy-le-Grand). 2018;64(7):51-55.
Sartini D, Morganti S, Guidi E, et al. Nicotinamide N-methyltransferase in non-small cell lung cancer: promising results for targeted anti-cancer therapy. Cell Biochem Biophys. 2013;67:865-873.
Campagna R, Pozzi V, Sartini D, et al. Beyond nicotinamide metabolism: potential role of nicotinamide N-Methyltransferase as a biomarker in skin cancers. Cancers (Basel). 2021;13(19):4943.
Lu XM, Long H. Nicotinamide N-Methyltransferase as a Potential Marker for Cancer. Neoplasma. 2018;65(5):656-663.
Tang SW, Yang TC, Lin WC, et al. Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 2011;32:138-145.
Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 2008;27:6679-6689.
Zhang J, Wang Y, Li G, Yu H, Xie X. Down-regulation of nicotinamide N-methyltransferase induces apoptosis in human breast cancer cells via the mitochondria-mediated pathway. PLoS One. 2014;9:e89202.
Yu T, Wang YT, Chen P, et al. Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress. Cell Physiol Biochem. 2015;35:710-721.
Bach D, Kim H, Bae SY, et al. Targeting nicotinamide N-methyltransferase and miR-449a in EGFR-TKI-resistant non-small-cell lung cancer cells. Mol Ther Nucl Acids. 2018;11:455-467.
Cui Y, Zhang L, Wang W, et al. Downregulation of nicotinamide N-methyltransferase inhibits migration and epithelial-mesenchymal transition of esophageal squamous cell carcinoma via Wnt/β-catenin pathway. Mol Cell Biochem. 2018;460:93-103.
You Z, Liu Y, Liu X. Nicotinamide N-methyltransferase enhances the progression of prostate cancer by stabilizing sirtuin. Oncol Lett. 2018;15:9195-9201.
Pozzi V, Mazzotta M, Lo Muzio L, et al. Inhibiting proliferation in KB cancer cells by RNA interference-mediated knockdown of nicotinamide N-methyltransferase expression. Int J Immunopathol Pharmacol. 2011;24:69-77.
Pozzi V, Sartini D, Morganti S, et al. RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One. 2013;8:e71272.
Sartini D, Seta R, Pozzi V, et al. Role of nicotinamide N-methyltransferase in non-small cell lung cancer: in vitro effectof shRNA-mediated gene silencing on tumourigenicity. Biol Chem. 2015;396:225-234.
Seta R, Mascitti M, Campagna R, et al. Overexpression of nicotinamide N-methyltransferase in HSC-2 OSCC cell line: effect on apoptosis and cell proliferation. Clin Oral Investig. 2019;23:829-838.
Pozzi V, Salvolini E, Lucarini G, et al. Cancer stem cell enrichment is associated with enhancement of nicotinamide N-methyltransferase expression. IUBMB Life. 2020;72(7):1415-1425.
Pissios P. Nicotinamide N-methyltransferase: more than a vitaminmB3 clearance enzyme. Trends Endocrinol Metab. 2017;28:340-353.
Mateuszuk Ł, Campagna R, Kutryb-Zając B, et al. Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. Biochem Pharmacol. 2020;178:114019.
Xie X, Yu H, Wang Y, et al. Nicotinamide N-methyltransferase enhances the capacity of tumorigenesis associated with the promotion of cell cycle progression in human colorectal cancer cells. Arch Biochem Biophys. 2014;564:52-66.
Xie X, Liu H, Wang Y, et al. Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. Oncotarget. 2016;7:45837-45848.
Li G, Fang S, Shao X, et al. Curcumin reverses NNMT-induced 5-fluorouracil resistance via increasing ROS and Cell cycle arrest in colorectal cancer cells. Biomolecules. 2021;11(9):1295.
Cui Y, Yang D, Wang W, et al. Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect. Mol Carcinog. 2020;59:940-954.
Wang Y, Zeng J, Wu W, et al. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. Breast Cancer Res. 2019;21:64.
Campagna R, Salvolini E, Pompei V, et al. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell Melanoma Res. 2021;34(6):1039-1048.
Eckert MA, Coscia F, Chryplewicz A, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569:723-728.
Harmankaya I, Akar S, Uğraş S, et al. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. J Obstet Gynaecol. 2021;41:248-253.
Yang J, Tong Q, Zhang Y, et al. Overexpression of nicotinamide N-methyltransferase mainly covers stroma of colorectal cancer and correlates with unfavorable survival by its product 1-MNA. J Cancer. 2021;12:6170-6181.
Zhao H, Li R, Chen Y, Yang X, Shang Z. Stromal nicotinamide N-methyltransferase orchestrates the crosstalk between fibroblasts and tumour cells in oral squamous cell carcinoma: evidence from patient-derived assembled organoids. Oncogene. 2023;42:1166-1180.